Vittoria Biotherapeutics to Present Phase 1 Results for Senza5 CART5 in T-Cell Lymphoma in an Oral Session and LampTAC Degrader Platform Data in a Poster Session at ASH 2026

On November 17, 2026 Vittoria Biotherapeutics, Inc. reported that results from the Phase 1 VIPER-101 study of Senza5 CART5 in relapsed or refractory T-cell lymphoma will be presented in an oral session, and preclinical data on its LampTAC protein degradation platform will be presented in a poster session at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will highlight clinical activity, CAR-T persistence, immune reconstitution, and delayed immune-mediated adverse events in heavily pre-treated patients with relapsed or refractory T-cell lymphoma. The presentation follows Vittoria’s announcement of U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation for Senza5 CART5, which was supported by this dataset, in addition to Orphan Drug designation.

"The responses we have seen in VIPER-101 strengthen our conviction that Senza5 CART5 can become a meaningful option for patients with relapsed or refractory T-cell lymphoma, who today have few effective choices," said Nicholas A. Siciliano, Ph.D., Chief Executive Officer of Vittoria Biotherapeutics.

A separate poster will describe LampTAC, a modular, genetically encoded protein degradation platform that enables cell-intrinsic protein control without genome editing and presents data supporting its potential for armoring in vivo CAR-T cells. Together, the presentations reflect Vittoria’s progress in building next-generation immunotherapies with a shared foundation in T-cell biology.

"Our work on CD5 has shown that modulating T-cell signaling pathways can make engineered T cells more potent. LampTAC is the evolution of that finding: a programmable, cell intrinsic protein degrader technology that can enhance in vivo engineered cells without genome editing. We look forward to presenting both datasets at ASH (Free ASH Whitepaper), and to advancing the distinct opportunities each represents," added Dr. Siciliano.

ASH 2026 Presentation Highlights and Details

VIPER-101 – Oral Presentation

Presentation title: High complete response rates, durable CD5-negative T-cell persistence, and mechanistically tractable delayed immune-mediated toxicity after low-dose CD5-edited CD5 CAR T-cell therapy in relapsed/refractory T-cell lymphoma
Presenter: Stefan K. Barta, M.D., M.S., Penn Medicine
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Cellular and Immune Therapies in T-Cell and NK-Cell Malignancies
Abstract / publication number: 908
Date, time and location: Monday, December 14, 2026; 3:00 to 3:15 PM CT (session 2:45 to 4:15 PM); Ernest N. Morial Convention Center, New Orleans Theatre B

LampTAC – Poster Presentation

Presentation title: LAMPTAC: A genetically encoded lysosome-targeting chimera platform for programmable, cell-intrinsic protein degradation can enable multiplexed engineering of in vivo CAR-T cells for heme indications
Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster III
Abstract / publication number: 5902
Date, time and location: Monday, December 14, 2026; 6:00:00 – 8:00:00 PM CT; MCCNO – Hall F

(Press release, viTToria biotherapeutics, NOV 17, 2026, View Source [SID1234674901])

Meet VAR2 Pharmaceuticals at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

On November 17, 2026 VAR2 Pharmaceuticals reported that it is attending the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona between 18-20 November 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our Executive Chairman of the Board Mads Daugaard will be accompanied by our Deputy Chief Medical Officer Thomas Clausen at the event. VAR2 Pharmaceuticals will feature a Late-breaking Poster Presentation (poster no. PB-011, abstract no. 26LBA) reporting on the results from our just completed Phase 0 Nuclear Imaging Basket Trial VARTUTRACE (NCT06645808).

We are looking forward to meeting old and new colleagues, and discussing potential synergies with our lead ADC program planned to start a Phase 1 in Q2 2027.

(Press release, Var2 Pharmaceuticals, NOV 17, 2026, View Source [SID1234674884])

Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 17, 2026 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, reported financial results for the three and nine months ended September 30, 2026, and provided an update on recent business progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Purple Biotech today has a focused set of assets: the CAPTN-3 platform, its lead candidate IM1240, and a second candidate, IM1305. That foundation was built under Gil Efron as Chief Executive Officer," said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. "My first priority is to bring IM1240 into a first-in-human study. What we believe sets CAPTN-3 apart is that its antibodies are designed to engage both T cells and NK cells against the tumor and to confine that activity to the tumor microenvironment. Many patients with advanced solid tumors do not respond to today’s immunotherapies, or relapse after an initial response. Those are the patients we are working for."

"Alongside our preparation of an IND application for IM1240, we continue to advance additional work on the platform. IM1240 data in treatment-resistant human tumor models will be presented this week in a plenary session at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium. Separately, we plan to report new preclinical data on IM1305, our second candidate, in the near term," Mr. Israel added. "As we previously reported, we are also bringing artificial intelligence into our antibody development. In our collaboration with Converge Bio, we are applying generative artificial intelligence to the design and optimization of our tri-specific antibodies, and we expect to provide an update on that work shortly. We believe artificial intelligence has the potential to make significant parts of drug development more efficient, and we intend to extend its use across the Company, with attention to data security and privacy."

Business Update:

IM1240 abstract selected for a plenary oral presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium

Data evaluating IM1240 in treatment-resistant human tumor models, including its multi-arm mechanism of action and the contribution of NKG2A engagement, as well as the pharmacokinetic and safety evaluation of CAPTN-3’s conditional CD3 masking approach, will be presented by Amir Horowitz, Ph.D., of the Icahn School of Medicine at Mount Sinai, in Plenary Session 7: Proffered Papers on Friday, November 20, 2026, at 15:00 CET (Abstract ENA26-0137).
U.S. patent granted for the CAPTN-3 platform

In September 2026, we received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering tri-specific antibody constructs and methods of use, and the patent was subsequently granted. The patent further strengthens our intellectual property portfolio and supports the development and partnering potential of the CAPTN-3 platform.
Financial Results for the Three Months Ended September 30, 2026

Research and Development Expenses were $0.4 million for the three months ended September 30, 2026, compared to $0.6 million for the same period in 2025, representing a decrease of $0.2 million. The decrease was primarily attributable to lower Chemistry, Manufacturing and Controls (CMC) and patent expenses.

General and Administrative Expenses were $0.7 million for the three months ended September 30, 2026, compared to $0.8 million for the corresponding period in 2025. The decrease was mainly due to lower consulting and non-cash bonus expenses.

Operating Loss was $1.1 million for the three months ended September 30, 2026, compared to $1.4 million for the corresponding period in 2025, representing a decrease of $0.3 million. The decrease was primarily attributable to lower research and development and general and administrative expenses.

Adjusted Operating Loss (as reconciled below) was $1.0 million for the three months ended September 30, 2026, compared to $1.3 million for the corresponding period in 2025.

Finance Income, Net was $0.1 million for the three months ended September 30, 2026, and for the corresponding period in 2025.

Net Loss was $1.0 million for the three months ended September 30, 2026, compared to $1.3 million for the corresponding period in 2025. The decrease was primarily attributable to lower operating expenses, and, to a lesser extent, to higher non-cash finance income resulting from changes in the fair value of outstanding warrants.

Adjusted Net Loss (as reconciled below) was $1.1 million for the three months ended September 30, 2026, compared to $1.2 million for the same period in 2025. Adjusted net loss excludes non-cash share-based compensation expenses and finance income or expenses resulting from changes in the fair value of outstanding warrants.

As of September 30, 2026, we had cash, cash equivalents and short-term deposits of $5.1 million, which, based on current management estimates and our current operating plan, are expected to provide us with a cash runway through late-2027.

Non-IFRS Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with International Financial Reporting Standards ("IFRS"), including adjusted operating loss and adjusted net loss. These non-IFRS measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similar measures presented by other companies. Adjusted operating loss and adjusted net loss adjust for non-cash share-based compensation expenses, and adjusted net loss also adjusts for finance income or expenses resulting from changes in the fair value of outstanding warrants. The Company’s management and board of directors utilize these non-IFRS financial measures to evaluate its performance. The Company provides these non-IFRS measures of its performance to investors because management believes that these non-IFRS financial measures, when viewed with its results under IFRS and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, these non-IFRS measures are not measures of financial performance under IFRS and, accordingly, should not be considered in isolation or as alternatives to IFRS measures as indicators of operating performance. Further, these non-IFRS measures should not be considered measures of the Company’s liquidity. A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

(Press release, Purple Biotech, NOV 17, 2026, View Source [SID1234674902])

Radspherin[®] shows favorable safety profile in the first interim safety readout from the ongoing randomized phase 2 trial in ovarian cancer

On November 17, 2026 Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, reported that no serious adverse event was related to Radspherin in the interim safety analysis of its ongoing randomized Phase 2 trial (RAD-18-003, NCT06504147) in patients with peritoneal metastases from advanced ovarian cancer. These are the first randomized, controlled safety data for Radspherin.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of the data cut-off on 30 October 2026, 74 patients had been randomized (2:1 – Radspherin : Control). The safety analysis set comprised 56 primary ovarian cancer patients who achieved complete surgical resection after neoadjuvant chemotherapy, of whom 40 received a single intraperitoneal dose of Radspherin (7 MBq) after surgery in addition to standard of care, and 16 received standard of care alone.

At this stage in the trial, there were no serious adverse events considered related to Radspherin, no deaths, and no adverse events leading to discontinuation. The proportion of patients with treatment-emergent adverse events (TEAEs, events reported on or after treatment start, regardless of cause) was similar in both arms. The safety profile of Radspherin remains consistent with previously published clinical data.

The majority of TEAEs in the experimental arm were considered unrelated to Radspherin and were consistent with the underlying disease and expected postoperative clinical course. At the patient level, the most frequent TEAEs in the experimental arm were constipation, anemia, abdominal pain, nausea and hypokalemia. A total of 10 events reported in five patients (12.5%) were considered as possibly related to Radspherin. These latter events were all mild or moderate (Grade 1 or 2) and included vomiting (2), nausea, abdominal pain, constipation, headache, dizziness, fatigue, anemia, and decreased lymphocyte count (one event each).

The trial’s Independent Data Monitoring Committee reviewed the unblinded safety data on 13 November 2026 and recommended that the trial continue without modification.

"Women in this trial have just been through neoadjuvant chemotherapy and major abdominal surgery, so any treatment added afterwards must be well tolerated," said Professor Ignace Vergote, gynaecologic oncologist and Professor Emeritus at the Catholic University Leuven, Belgium. "It is encouraging to now see this in randomized data. The adverse events observed in both arms of the trial are what we would expect in patients recovering from this type of surgery, which is reassuring for patients and their physicians."

These randomized data are consistent with the safety profile seen in previous Radspherin trials: the safety run-in cohort of this trial, completed in March 2025, the Phase 1 trial in recurrent ovarian cancer (RAD-18-001, n=21) and the Phase 1/2a trial in colorectal cancer (RAD-18-002, n=47), in which no dose-limiting toxicity was observed at the recommended dose of 7 MBq [1,2].

"These first randomized data are an important milestone for Oncoinvent and for the Radspherin program," said Dr Zuzana Jirakova Trnkova, Chief Medical Officer of Oncoinvent. "The safety profile is in line with what we have reported in previous studies, which strengthens our confidence as we move towards the efficacy readout in the spring and readiness for Phase 3. We thank the patients, investigators and site teams who made this possible."

Recruitment in the phase 2 trial is expected to complete in the first half of 2027. The interim efficacy readout, planned for April 2027, will include close to all randomized patients, of whom approximately 40 will have at least nine months of follow-up.

Notes on Safety Terminology

Adverse event: An unintended medical event reported by a patient during the trial, regardless of whether it is related to the trial drug.
Treatment-emergent adverse events: Any unintended medical event that began or worsened after the patient received the first dose of the trial drug, whether or not it was caused by the drug.
Serious treatment-emergent adverse events: A major medical event (such as hospitalization or a life-threatening condition) that began or worsened after treatment started, regardless of whether it was linked to the trial drug.

(Press release, Oncoinvent, NOV 17, 2026, https://www.oncoinvent.com/press-release/radspherin-shows-favorable-safety-profile-in-the-first-interim-safety-readout-from-the-ongoing-randomized-phase-2-trial-in-ovarian-cancer/ [SID1234674886])

CancerVax Successfully Kills Cancer Cells in Landmark Test

On November 17, 2026 CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that "tricks" the body’s immune system into fighting cancer, reported that it has successfully killed human liver-derived cancer cells in-vitro.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CancerVax platform is designed to harness a patient’s existing antiviral immunity to detect, mark and kill cancer cells with precision. At its core is a proprietary two-stage targeting system that combines ligand-conjugated lipid nanoparticles (Marker1 LNP) with a novel Polyepitope Smart mRNA technology (Marker2). Together, this LNP-mRNA therapy is designed to selectively seek out cancer cells and force them to express multiple viral antigens, effectively making them look virally infected. The body’s existing antiviral T-cells can then recognize and kill these marked cancer cells, as if they were common diseases.

Unlike personalized cancer vaccines being developed by Moderna, Merck, and BioNTech, which are custom-designed and manufactured for each patient, CancerVax is developing an off-the-shelf, potentially universal cancer immunotherapy. By harnessing existing antiviral immunity rather than targeting each tumor’s unique mutations, CancerVax aims to treat multiple cancer types without developing patient-specific one-off medicines. This approach potentially simplifies manufacturing, reduces costs, and broadens patient access. The Company believes that redirecting the body’s powerful, and broad antiviral immunity against cancer may offer a more effective approach than attempting to generate new and narrow immunity against patient-specific tumor mutations.

The Results

In the experiment, liver cancer cells were exposed to CancerVax Marker1 LNPs containing Polyepitope Smart mRNA before antiviral T-cells were added.

The expressed viral epitopes induced potent cancer-cell killing by human donor-derived CMV-specific T-cells that were isolated and expanded for laboratory testing. CancerVax achieved up to 100% normalized cytolysis. In addition to CMV-specific T-cells, the same Polyepitope Smart mRNA enabled influenza-specific T-cell killing, reaching 66% normalized cytolysis under the highest-dose test conditions. Together, these findings provide important proof of concept for the Company’s multi-virus approach to redirecting existing antiviral immunity against cancer cells, and the potential systemic treatment of multiple cancer types.

The Study

In the study, human liver-derived cancer cells were treated with one of the following reagents:

Marker1 LNP + Marker2 Polyepitope Smart mRNA
Marker1 LNP + Marker2 Luciferase Smart mRNA (negative control 1)
Non-matching peptide (negative control 2)
Matching peptide (positive control)
After 24 hours, cancer cell media was replaced. Following the media change, HLA-matched CMV or influenza antigen-specific CD8+ T-cells were co-cultured with the liver cancer cells at low and high ratios. Cancer-cell killing was tracked continuously in real time by impedance measurement over 68 hours.

"Different people have different levels of immunity to common viruses," said Dr. Adam Grant, CancerVax Principal Scientist. "Some may have stronger immunity to CMV, while others may have stronger responses to influenza or measles. That’s why our multi-virus approach is so critical. By demonstrating that the same Smart mRNA construct can enable cancer-cell killing through both CMV and influenza-specific T-cells, we’ve taken an important step toward a therapy designed to harness the diverse antiviral immunity that people already possess. As announced previously, our polyepitope design predicts potential coverage of 99.5% of the global population. These results represent a pivotal milestone in demonstrating the broad applicability of our multi-virus approach."

"These results provide strong evidence that our Smart mRNA can mark cancer cells for recognition and killing by human antiviral T-cells," said Dr. George Katibah, CancerVax Chief Scientific Officer. "Our control experiments support an antigen-specific response, consistent with the mechanism we designed the platform to achieve. This is an important proof of concept in cell culture. Our next step is to evaluate tumor targeting, safety, and antitumor activity in animal studies."

"CancerVax has truly reached a landmark," said Byron Elton, CancerVax CEO. "For the first time, we have demonstrated the complete therapeutic sequence of detecting cancer cells, marking them as known viruses, and tricking the body into killing cancer. This milestone clearly signals the Company’s transition from a novel idea to an exciting reality."

Mr. Elton concluded, "Major biopharmaceutical companies and venture capital firms are investing heavily in the cancer immunotherapy and cancer vaccine space. Like us, they recognize that the body itself may be our most effective weapon in the fight against cancer. In fact, Dr. Anthony Letai, director of the National Cancer Institute, recently announced a national initiative to accelerate the clinical development of therapeutic cancer vaccines. We believe CancerVax is a big idea and we’re in the right place, at the right time, with the right technology."

To learn more about the CancerVax platform, please watch the Short Explainer Video at View Source

(Press release, CancerVax, NOV 17, 2026, View Source [SID1234674903])